DWTX — Dogwood Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Virios Therapeutics Announces Publication of International Patent For IMC-2 Covering Antiviral Treatment Of Long-COVID
Brief: Virios Therapeutics Q4 EPS USD -0.06
Brief: Virios Therapeutics Says All Employees Have Agreed To 10% Salary Compensation Reduction In Exchange For Future Vesting Stock Options
Brief: Virios Therapeutics Says On Feb 26, Approved 10% Salary Reduction For Each Employee Of Co, Including Each Of Co’s Executive Officers, Effective March 1
Brief: Virios Therapeutics Says Co Continues To Actively Explore Opportunities For Three Initiatives
Brief: Virios Therapeutics Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
Brief: Virios Therapeutics Q3 EPS USD -0.06
Brief: Virios Therapeutics Announces Termination Of At-The-Market Sales Agreement
Brief: Virios Therapeutics Announces Halt To At-The-Market Offering Sales
Virios Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
U.S. STOCKS ON THE MOVE-ANI Pharmaceuticals, Heritage Insurance, Mirati
U.S. STOCKS ON THE MOVE-Marqeta, Natgas firms, Bumble
U.S. STOCKS ON THE MOVE-Toast, Axon Enterprise, Decibel Therapeutics
Virios rises on plans to advance lead candidate to late-stage study
Brief: Virios Therapeutics Says Plans To Advance Lead Candidate IMC-1 To Phase 3 Development For Treatment Of Fibromyalgia
Virios Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: Virios Therapeutics Announces Positive Data of Drug Combination To Treat Multiple Long-Covid Symptoms In A Study
Brief: Virios Therapeutics Entered Into A Capital On Demand(Tm) Sales Agreement With Jonestrading Institutional Services
Brief: Virios Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement